Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 2/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386637 | 1.00 | POLB (0.51) | POLBL3MBTL1TAAR1DRD2SELP | |
| SCHEMBL6392368 | 0.85 | CCNA2 (0.41) | POLBL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL6390900 | 0.85 | CCNA2 (0.41) | POLBL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL6388703 | 0.85 | CCNA2 (0.41) | POLBL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL6506411 | 0.84 | SMN1; SMN2 (0.44) | L3MBTL1 | |
| SCHEMBL6390689 | 0.83 | ALDH1A1 (0.50) | POLBL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL6504984 | 0.81 | SMN1; SMN2 (0.44) | POLBNPC1RAB9AHPGDHCRTR1 | |
| SCHEMBL6388874 | 0.81 | SMN1; SMN2 (0.44) | POLBNPC1RAB9AHPGDHCRTR1 | |
| SCHEMBL6387573 | 0.81 | SMN1; SMN2 (0.44) | POLBNPC1RAB9AHPGDHCRTR1 | |
| SCHEMBL6504082 | 0.81 | MEN1 (0.39) | POLBTAAR1DRD2ALDH1A1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | POLB 1038/4885L3MBTL1 4470/4885TAAR1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.